Pilot: Pharmaceutical initiative to aid drug development in knee osteoarthritis – EU APPROACH Project
GaitSmart is one of the partners in the APPROACH project and the only gait measurement tool, working alongside Merck, GSK and Servier and leading European hospitals.
The APPROACH project brings together European clinical centers, basic research institutes, small- and medium-sized businesses and pharmaceutical companies. Together, they will combine biomedical data from more than 10 000 people with and without osteoarthritis into a unified bioinformatics platform with the aim of identifying different OA phenotypes. These phenotypes will then be validated in a longitudinal cohort using existing and newly-developed biomarkers. This will allow for the development of guidelines for differentially diagnosing the right patient for the right treatment.
GaitSmart is being used to test three hundred people with specific phenotypes over a two year period.
The results will allow for the development of guidelines for differentially diagnosing the right patient for the right treatment.